Digital gene discovery integrated with targeted validation and in-depth analysis
HELSINKI, FINLAND, 2 October 2012: Plexpress, developer of the innovative TRAC platform for high-throughput gene expression analysis, has announced a new collaboration with MediSapiens, a specialist in cloud computing, software and the user-friendly mining of vast genomic databases. The companies have launched the new OncoTRAC™ Gene Expression Service, which takes advantage of MediSapiens’ extensive IST Online Gene Expression Database to facilitate the rapid, reliable identification of relevant genes of interest. After this initial discovery phase, the Plexpress FAST TRAC Gene Expression Analysis technology is used to assay the expression of a hand-selected 30-gene panel in a large number of samples. The unique combination of these two complimentary approaches presents a complete solution from gene discovery through to validation and in-depth study, across a wide range of drug development, biomarker discovery and life science research applications.
Tommi Pisto, CEO of MediSapiens, commented: “With a database of over 20,000 samples and 300 million data points, our MediSapiens IST Online Gene Expression Viewer is the world’s largest unified gene expression database. The new OncoTRAC Service will allow users to leverage this data to discover new genes and then investigate their biological relevance.” Visualizing a gene’s function across all tissues and exploring relationships between expression and disease, the database allows the straightforward integration of proprietary data, whilst strict normalization also allows the comparison of results from a wide spectrum of studies. Exploration and identification of the most relevant genes of interest from a pool of samples of various cancer types, treatment-response and disease grades are subsequently compared with expression in healthy tissue, providing a knowledge-based discovery approach.
CEO of Plexpress, Dr Jari Rautio, said: “TRAC is the ideal technology for following up genomic discovery using the IST Online Gene Expression Viewer, as it allows the multiplex analysis of up to 30 genes in hundreds to thousands of samples. In this way, researchers can really investigate the biology of their system in considerable depth, without sacrificing the number of genes they can assay in each sample.” The other benefits of the fully automatable TRAC process include increased assay speed, as well as reduced technical variation, hands-on time and assay cost when compared with similar methods such as qPCR and microarray analysis. While TRAC offers the flexibility to create custom gene panels, pre-validated catalogue libraries are also available for specific applications such as ADME-Tox studies, ready for rapid, ‘off-the-shelf’ utilization.
For more information please visit the Plexpress website at www.plexpress.com
Plexpress was established as a spinoff from the Finnish Technology Research Center VTT in 2007. Including R&D at VTT, the company’s TRAC technology has been developed continuously for nearly 10 years and it has been documented in over 15 publications. The technology was originally developed for demanding bioprocess applications, which required a very robust solution for gene expression analysis. Since starting operations in 2008, the company has carried out over 50 projects using the TRAC technology in the fields of pharmaceutical development and academic research.
For further information see: www.plexpress.com
MediSapiens is a bioinformatics company developing inspiring web applications for genomics researchers, pharmaceutical industry and personalized medicine. MediSapiens has unique know-how in developing software solutions for integration of both molecular and clinical data from preclinical models to interpreting comprehensive molecular profiles of individual cancer patients in clinical settings. Based on the world’s largest unified gene expression database, MediSapiens’ platform extends into highly tailored solutions to meet the exact needs of various demanding research environments.
For more information visit www.medisapiens.com or email firstname.lastname@example.org
Product EnquiriesPlexpressDr Jari Rautio: CEO Plexpresst: +358 40 504 0355 e: email@example.com: www.plexpress.com
Media enquiriesAlto Marketing LimitedDr Paul Avery: Account Director – Life Science
t: +44 (0)1489 557672 e: firstname.lastname@example.org